Mass Tort Client Intake in 2026: Costs, Benchmarks and Strategy

The Intake Bottleneck That Quietly Kills Mass Tort ROI

Mass tort client intake is the operational and financial backbone of any plaintiff firm competing for high-volume litigation dockets, directly determining cost-per-retained-client, case economics, and ultimately portfolio ROI. As claimant pools expand and advertising costs rise, the gap between a qualified lead and a signed retainer has become the single most consequential conversion point in plaintiff-side litigation. Firms that measure and systematically optimize that gap retain more cases at lower cost. Firms that do not bleed inventory they already paid to acquire.

What Mass Tort Client Intake Actually Means for Your Bottom Line

In a general legal context, client intake is the process of gathering information from a potential client, evaluating whether the case fits the firm's practice, and moving that person from prospect to signed client. In mass torts, the stakes and the complexity are both significantly higher.

Mass tort litigation involves large claimant pools, strict eligibility criteria driven by MDL or settlement parameters, document-intensive qualification, and tight windows where advertising dollars produce the best return. A defective medical device tort might require a specific product model, a confirmed implant date, a revision surgery, and medical records documenting the injury. A pharmaceutical tort might hinge on dosage, duration of use, and a diagnosed condition from a treating physician. Miss any of those criteria during intake and you have signed a case that will never resolve, or you have turned away a valid claimant because your intake team asked the wrong questions.

Mass tort client intake is not a clerical function. It is a revenue function. Treat it like one.

The Four Major Categories of Mass Torts and Why Each Demands Different Intake Logic

Firms new to this space sometimes assume that intake is intake. It is not. The qualification criteria, required documentation, and common disqualifying factors vary meaningfully across tort categories.

• Defective products: Roundup, CPAP devices, hernia mesh, talcum powder. These require proof of product use, specific injury diagnoses, and often purchase or prescription records. Roundup cases, for example, require a non-Hodgkin lymphoma diagnosis. CPAP cases under the Philips Respironics MDL required specific device model numbers. A lead without model documentation had limited value early in that litigation.
• Environmental and toxic exposure: Camp Lejeune is the defining example of the past three years. Intake there requires confirming residence or service on base during a specific date range, a qualifying diagnosis, and military or housing records. The documentation burden is high, and leads without those records stall in qualification for months.
• Pharmaceutical injuries: NEC baby formula, Zantac, Elmiron. These often require pharmacy records, medical records confirming diagnosis, and sometimes expert review before a case is signed. Intake has to screen efficiently enough to identify qualified claimants without running up evaluation costs on unqualified leads.
• Mass casualty and negligence events: Fires, structural failures, disasters. These are typically more geographically concentrated, faster-moving, and require incident-specific documentation. Intake speed matters more here than in slow-burning pharmaceutical litigation.

Understanding which category you are working in changes how you staff intake, what questions your intake form prioritizes, and how aggressively you pursue document collection upfront versus post-sign.

The Numbers: What Good Mass Tort Client Intake Economics Look Like

Let's put real numbers on this. The economics vary by tort, but here are the benchmarks that a well-run firm should be hitting or targeting.

A qualified lead in an active mass tort today might cost anywhere from $200 to $1,500 depending on the tort, the channel, and how competitive the advertising market is. Cost per signed case typically runs two to four times the cost per lead, because not every lead converts. A firm signing cases at a 35 to 45 percent lead-to-signed rate is performing well. Below 25 percent, something is broken, either in lead quality, intake speed, or the qualification script itself.

Speed matters more than most firms acknowledge. Research from contact-rate studies across industries consistently shows that leads contacted within five minutes of submission convert at dramatically higher rates than leads worked an hour later. In mass torts, where a potential claimant may have submitted their information to three firms simultaneously, the first firm to reach them with a clear, confident intake call wins the case. Waiting until Monday morning to work Friday's leads is not a strategy. It is a donation to your competitors.

Document collection is the other conversion killer. Firms that require medical records before signing lose qualified claimants who cannot navigate that process alone. The better approach is to sign on confirmed verbal qualification and pursue records post-retainer, with a dedicated document collection team or service handling the follow-up.

How to Execute Mass Tort Client Intake at a High Level

High-converting intake operations share several characteristics that separate them from firms leaving money on the table.

Build or Outsource a Dedicated Intake Team

General intake staff handling personal injury, workers' comp, and mass torts simultaneously are not positioned to qualify complex mass tort cases accurately or quickly. The qualification criteria are too specific. A Camp Lejeune call requires different questions than a talcum powder call. Dedicated intake specialists trained on a single tort or a small group of related torts outperform generalist staff on both conversion rate and case quality.

The outsource-versus-in-house decision comes down to volume and timeline. If you are running a single tort at moderate volume, building in-house makes sense. If you are running multiple torts simultaneously, or ramping volume quickly as a new MDL develops, outsourcing mass tort client intake to a specialized service lets you scale without the hiring and training lag.

Build the Right Technology Stack

This is where a lot of firms are still operating in 2015. A modern mass tort intake operation runs on a CRM built for legal intake, not a generic sales CRM with fields relabeled. Filevine, Litify, and LeadDocket are the platforms most commonly used by high-volume plaintiff firms. They allow you to track leads from first contact through signed retainer, measure conversion at each stage, and identify where leads are dying.

AI is beginning to play a real role here, and firms that are not paying attention will find themselves at a cost disadvantage. AI-driven intake screening can handle initial lead qualification at scale, routing only verified qualified leads to human intake specialists. That reduces labor cost per signed case and increases speed of contact. If your firm is not thinking about where AI fits into intake operations, it is worth reading through "A Lawyer's Guide to AI," which covers practical applications for plaintiff firms in plain language.

Qualify With Precision, Not Assumptions

Your intake script has to be built around the current MDL criteria, not a generic checklist. MDL settlement matrices shift over time. What qualified a case in year one of a litigation may not produce a compensable case in year three. Work with your MDL counsel to keep intake criteria current, and audit your signed inventory periodically to catch qualification drift before it becomes a write-off problem.

Pitfalls and Compliance Risks Firms Underestimate

The bar rules around non-lawyer intake staff vary by state but are consistent on one core point: intake staff cannot give legal advice, and attorney-client privilege attaches only once representation is established. Firms using third-party intake vendors need written agreements that clearly define the scope of services, confirm confidentiality obligations, and avoid any structure that looks like fee-splitting with a non-lawyer entity.

TCPA and CIPA exposure in intake is real and growing. Firms using text or automated outreach to work inbound leads need to have consent documentation in place before that contact happens. The lead intake form should capture explicit consent to be contacted by the firm. If you are buying leads from a third-party vendor, you need to verify that the consent captured by that vendor covers contact from your firm specifically, not just generic legal advertising.

Data security is the other compliance area that gets minimal attention until a breach happens. Mass tort intake collects sensitive medical and personal information at volume. That data needs to be handled under a security framework consistent with your state bar's technology competence obligations and, where applicable, HIPAA. Storing case intake data in an unencrypted spreadsheet or a generic cloud storage folder is not acceptable.

How MTAA Approaches This for Client Firms

At Mass Tort Ad Agency, we have managed more than $250 million in Facebook ad spend for over 600 plaintiff law firms across more than 100 torts. The advertising side is what we are known for, but we have seen enough intake operations from the inside to know that ad performance and intake performance are inseparable. A campaign delivering leads at $300 cost-per-lead with a 40 percent intake conversion rate outperforms a campaign at $150 cost-per-lead with a 15 percent conversion rate every time.

Our pricing model is transparent: ad spend plus a 15 percent management fee, no markup on media, no hidden costs. That structure means our incentive is aligned with yours. We want the leads to convert into signed cases, because that is what keeps firms running campaigns with us long-term. We work directly with firms on intake criteria alignment, making sure the qualification questions in our lead forms match what the intake team is screening for, which reduces friction and improves conversion before a human ever picks up the phone.

Build Intake to Win, Not Just to Process

Mass tort litigation is a long-cycle business. A case signed today may not resolve for three to five years. That timeline makes the economics of acquisition and intake even more important, because every dollar spent inefficiently at the front end compounds over the life of the case. Firms that treat mass tort client intake as a strategic function, staff it properly, measure it rigorously, and update it as litigation criteria evolve are the ones that build sustainable mass tort practices. Firms that treat it as a phone-answering exercise will keep wondering why their advertising spend is not producing the returns they expected. Your intake operation is either an asset or a liability. The goal is to build something that makes every lead dollar work harder, and that starts with understanding exactly what good mass tort client intake looks like in practice.